Skip Navigation Links.

Kilitch Drugs (India) Ltd


BSE: 524500 | NSE: KILITCH | ISIN: INE729D01010 
Market Cap: [Rs.Cr.] 29 | Face Value: [Rs.] 10
Industry: Pharmaceuticals - Indian - Formulations

 Discuss this stock

Board Meet

30-May-13 
Audited Results 
12-Feb-13 
Quarterly Results 
15-Jan-13 
Kilitch Drugs India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on January 15, 2013, inter alia, to consider sale of investments made by the Company. Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 15, 2013, was decided the following : - To disinvest company's entire stake held in Eye Kare Kilitch Ltd, being a non-listed Company, as the Board of Directors do not envisage any increase in growth on the said investment without any additional infusion of funds, which the Board do not find it feasible. (As per BSE Announcement Dated on 15.01.2013) 
09-Nov-12 
Quarterly Results 
30-Aug-12 
Kilitch Drugs India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 30, 2012, inter alia, to consider the following business: 1. To recommend Special Interim Dividend on equity shares of the Company; 2. To fix the record date for the purpose of Special Interim Dividend; 3. To take on record the Audited Consolidated Financial Results of the Company for the year ended March 31, 2012; 4. To adopt and approve the Notice & Directors Report of the Company along with the Corporate Governance Report for financial year 2011-12; 5. To finalize the date, venue and time for convening 20th Annual General Meeting of the Members of the Company; Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 30, 2012, inter alia, 1. Declared Special Interim dividend @ 300% (i.e. Rs.30/- per equity share of Rs.10/- each) on the equity shares of the Company. 2. Decided to convene the 20th Annual General Meeting of the Members of.the Company at the Registered Office of the Company at C-301/2. MIDC, TTC Industrial Area, Pawane Village, Thane: 400701 on September 29, 2012 at 9.30A.M (As per BSE Announcement Dated on 30.08.2012) 

AGM

29-Sep-12
AGM : 29.09.2012 Kilitch Drugs India Ltd has informed BSE that the 20th Annual General Meeting (AGM) of the Company was held on September 29, 2012. (As Per BSE Announcement Dated on 01.10.2012) 
10-Sep-11
AGM 30.08.2011 Kilitch Drugs India Ltd has informed BSE as under: 'The 19th Annual General Meeting (hereinafter referred to as the said AGM) of the Members of the Company was scheduled to be held on Tuesday, August 30, 2011 at its Registered Office at C-301/2, MIDO, TTC I Industrial Area, Pawane Village, Thane: 400701 at 9.00 A.M. However, the working Directors of the Company, who are well versed and have firsthand information and knowledge about the business operations of the Company unfortunately will not be in a position to attend the said AGM due to sudden business exigencies, which cannot be avoided. Further, the presence of such working Directors in the said AGM is all more important in order to answer any queries and in particular, about the operations of the Company, that may be raised by shareholders of the Company. Also, any queries raised by the members about future business plans can be well attended to only by such Directors who oversee day to day business operations of the Company. In view of the above, it is proposed to extend the date of 19th Annual General Meeting from Tuesday, August 30, 2011 to Saturday, September 10, 2011 at the same venue and at the same time. Further the dates of book closures as intimated to your esteemed exchange vide our letter dated July 25, 2011 remains unchanged from August 23, 2011 to August 30, 2011 [both days inclusive]. (As Per BSE Announcement Website dated on 03.08.2011) Kilitch Drugs India Ltd has conveyed its 19th Annual General Meeting on September 10, 2011, for the financial year 2010-11 and has passed the following Ordinary Resolutions for: 1. Adoption and Approval of the Audited Annual Accounts for financial year 2010-11. 2. Declaration of dividend @ 10% i.e. Re.1/- on Rs.10/- per share on 13231828 equity shares of Rs. 10/- each aggregating to Rs 13231828/-. 3. Re-appointment of Mr. Bhavin Mehta as Director of the Company. 4. Re-appointment of Mr. Parikaj Kamdar as Director of the Company. 5. Appointment of M/s RNR Iyer & Co., Chartered Accountants, as Statutory Auditors of the Company. 6. Re-Appointment of Mr. Mukund Mehta as Managing Director of the Company. 7. Re-Appointment of Mr. Paresh Mehta as Whole Time Director designated as Joint Managing Director of the Company. 8. Re-Appointment of Mrs. Neelima Waingankar as Whole Time Director of the Company. (As Per BSE Announcement Website dated on 10.09.2011) 
20-Sep-10
AGM 20/09/2010 Kilitch Drugs India Ltd has now informed BSE that the Board of Directors at their meeting held on August 10, 2010 had recommended the dividend of Rs. 1/- (10%) on Rs. 10/- per share on 13202122 equity shares of Rs. 10/- each aggregating to Rs. 13202122/- subject to the approval of the members at the forthcoming 18th Annual General Meeting which is scheduled to be held on September 20, 2010. (As Per BSE Announcement Dated on 16.09.2010) Kilitch Drugs India Ltd has informed BSE that the members at the 18th Annual General Meeting (AGM) of the Company held on September 20, 2010, inter alia, have passed the following Ordinary resolutions for : 1. Adoption and Approval of the Audited Annual Accounts for financial year 2009-10. 2. Declaration of dividend @ 10% i.e. Rs. 1/- on Rs. 10/- per share on 13202122 equity shares of Rs. 10/- each aggregating to Rs. 13202122/-. 3. Re-appointment of Mr. Mukesh Shah, Mr. Hemang Engineer & Mr. Shailesh Chheda as Directors of the Company; 4. Appointment of M/s. RNR Iyer & Co., Chartered Accountants, as Statutory Auditors of the Company. (As Per BSE Announcement Website dated on 20.09.2010) 
22-Sep-09
AGM 22.09.2009 Kilitch Drugs India Ltd has informed BSE that the members at the 17th Annual General Meeting (AGM) of the Company held on September 22, 2009, inter alia, have passed the following resolutions: 1. Adoption and Approval of the Audited Annual Accounts for financial year 2008-09. 2. Declaration of dividend @ 10%. 3. Re-appointment of Mrs. Nilima Waingankar as Director of the Company. 4. Re-appointment of Mr. Bhavin Mehta as Director of the Company. 5. Re-appointment of Mr. Pankaj Kamdar as Director of the Company. 6. Appointment of M/s. R. S. Negi & Co., Chartered Accountants, as Statutory Auditors of the Company. (As Per BSE Announcement Website dated on 25.09.2009) 
22-Sep-08
AGM 22/09/2008 Kilitch Drugs India Ltd has informed BSE that the members at the 16th Annual General Meeting (AGM) of the Company held on September 22, 2008, inter alia, have accorded to the following: 1. Adoption of the audited Balance Sheet as at March 31, 2008 and the Profit and Loss Account for the year ending March 31, 2008 together with the Auditors Report and the Directors Report thereon along with the annexures thereto. 2. Confirmation of dividend at the rate of 10% per equity share capital of the Company of Rs 10 each for the year ended March 31, 2008. 3. Re-appointment of Mr. Mukund P Mehta & Mr. Mukesh Shah, as Directors of the Company, liable to retire by rotation. 4. Re-appointment of M/s. R S Negi & Co., Chartered Accountants, Mumbai as Auditors of the Company to hold office until the conclusion of the next Annual General Meeting of the Company, on remuneration, terms & conditions. 5. Appointment of Mr. Nitin R Shah, Mr. Bhavin Mehta, Mr. Pankaj Kamdar, Dr. Mahalingam Vasudevan, Mr. Deepak Shenoy, Mr. Shailesh Chheda & Mr. Hemang Engineer, as Directors of the Company liable to retire by rotation. 6. Appointment of Mr. Nitin R Shah, as Whole time Director of the Company for a period of five years with effect from October 01, 2007 to September 30, 2012, on remuneration, terms & conditions. (As per BSE Announcement dated on 24/09/2008) 

EGM

31-May-10
Extra ordinary general meeting of the members of the Company on May 31, 2010. Kilitch Drugs India Ltd has informed BSE that the members at the Extra Ordinary General Meeting (EGM) of the Company held on May 31, 2010, inter alia, have passed the following resolutions: 1. Authorising the Board of Directors to re-price the Options already granted by the Company under KDL ESOS 2007, subject to provisions contained in Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme Guidelines, 1999) and other applicable enactments. 2. Appointment of M/s. RNR IYER & CO., Chartered Accountants, Mumbai, as the Statutory Auditors of the Company to fill-in the casual vacancy caused by the resignation of M/s. R. S. Negi & Co, Chartered Accountants, Mumbai. (As Per BSE Announcement Dated on 31.05.2010) 
11-Aug-08
Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 11, 2008, inter alia, has transacted the following business: The Board has decided to call an Extra Ordinary General Meeting of the shareholders, on August 11, 2008, for seeking their approval to the proposed issue of the Warrants. Kilitch Drugs India Ltd has informed BSE that an Extra Ordinary General Meeting (EGM) of the members of the Company will be held on August 11, 2008, inter alia, have accorded to the following: 1. To increased the Authorised Share Capital of the Company from Rs 15,00,00000/- (Rupees Fifteen Crore) divided into 1,50,00,000 (One Crore Fifty Lac) Equity shares of Rs 10/- (Rupees Ten) each, to Rs 20,00,00,000/- (Rupees Twenty Crore) divided into 2,00,00,000 (Two Crore) Equity shares of Rs 10/- (Rupees Ten) each and consequential amendments in Memorandum & Articles of Association of the Company. 2. To offer, issue and allot, 29,00,000 (Twenty Nine Lac) warrants, on a Preferential allotment basis for cash, to the persons and for entities as stated in the table here below: 1. Name of the entity : Sophia Growth - a share class of somerset India Fund - No of warrants to be allotted : 7,00,000 2. Name of the entity : India Max Investment Fund Ltd - No of warrants to be allotted : 6,00,000 3. Name of the entity : Narayan Tulsidas Rathi - No of warrants to be allotted : 75,000 4. Name of the entity : Rafat Sultan - No of warrants to be allotted : 75,000 5. Name of the entity : NBZ Pharma Ltd - No of warrants to be allotted : 13,00,000 6. Name of the entity : Mukesh Damji Shah - No of warrants to be allotted : 50,000 7. Name of the entity : Finaventure Advisory Services India Pvt Ltd - No of warrants to be allotted : 1,00,000 providing the holders of warrants a right to subscribe for one fully paid up equity share of Rs 10 each, for every warrant held, at a subscription price (inclusive of premium) per Equity Share of Rs 120, being the price worked out higher than the one in accordance with the Guidelines for Preferential Issues, of Chapter XIII of the SEBI (DIP) Guidelines 2000, subject to remuneration, terms and conditions. (As Per BSE Announcement Website Dated on 21.07.2008) Kilitch Drugs India Ltd has informed BSE that the members at the Extra Ordinary General Meeting (EGM) of the Company held on August 11, 2008, inter alia, have accorded to the following: 1. Increase in the Authorised Share Capital of the Company from Rs 15,00,00,000/- (Rupees Fifteen Crore) divided into 1,50,00,000 (One Crore Fifty Lac) Equity shares of Rs 10/- (Rupees Ten) each, to Rs 20,00,00,000/- (Rupees Twenty Crore) divided into 2,00,00,000 (Two Crore) Equity shares of Rs 10/- (Rupees Ten) each and consequential amendments in Memorandum & Articles of Association of the Company. 2. Authority to the Board to offer, issue and allot, 29,00,000 (Twenty Nine Lac) warrants, on a Preferential allotment basis for cash, to the persons and for entities as stated in the table here below: 1. Name of the entity : Sophia Growth - a share class of somerset India Fund - No of warrants to be allotted : 7,00,000 2. Name of the entity : India Max Investment Fund Ltd - No of warrants to be allotted : 6,00,000 3. Name of the entity : Narayan Tulsidas Rathi - No of warrants to be allotted : 75,000 4. Name of the entity : Rafat Sultan - No of warrants to be allotted : 75,000 5. Name of the entity : NBZ Pharma Ltd - No of warrants to be allotted : 13,00,000 6. Name of the entity : Mukesh Damji Shah - No of warrants to be allotted : 50,000 7. Name of the entity : Finaventure Advisory Services India Pvt Ltd - No of warrants to be allotted : 1,00,000 providing the holders of warrants a right to subscribe for one fully paid up equity share of Rs 10 each, for every warrant held, at a subscription price (inclusive of premium) per Equity Share of Rs 120, being the price worked out higher than the one in accordance with the Guidelines for Preferential Issues, of Chapter XIII of the SEBI (DIP) Guidelines 2000, subject to remuneration, terms and conditions. (As per BSE Announcement Website dated on 13/08/2008) 
28-May-07
Kilitch Drugs India Ltd has informed BSE that an Extra-Ordinary General Meeting (EGM) of the members of the Company will be held on May 28, 2007, inter alia, to transact the following business: 1. Increase in the Authorized Share Capital of the Company from Rs 10,00,00,000/- divided into 1,00,00,000 Equity Shares of Rs 10/- each to Rs 15,00,00,000/- divided into 1,50,00,000 Equity Shares of Rs 10/- each and consequential amendments in the Memorandum and Articles of Association of the Company. 2. To offer, issue and allot 6145000 Equity shares to the following allottees: i. NBZ Pharma Ltd (Promoter Group) - 6000000 No of Shares ii. Ms. Neha Rathi (Non Promoter) - 100000 No of Shares iii. Ms. Pravina Mehta (Non Promoter) - 25000 No of Shares iv. Mr. Sanjeev Nandu (Non Promoter) - 10000 No of Shares v. Mr. Mahendra A Chheda (HUF) (Non Promoter) - 10000 No of Shares of face value of Rs 10/- each at a subscription price of Rs 47.50/- per Equity share inclusive of premium of Rs 37.50/- per Equity Share, or at price as may be mutually agreed but not less than price calculated as per DIP Guidelines 13.1.1.1 being higher of the following: (a) The average of weekly high and low of the closing prices of the related shares quoted on the Stock exchange during the six months preceding the relevant date or (b) The average of weekly high and low of the closing prices of the related shares quoted on the stock exchange during the two weeks preceding the relevant data, per equity shares on a Preferential allotment basis for cash on the terms and conditions. Kilitch Drugs India Ltd has informed BSE that the members at the Extra Ordinary General Meeting (EGM) of the Company held on May 28, 2007, inter alia, have accorded to the following: 1. Increase in the Authorized Share Capital of the Company from Rs 10,00,00,000/- divided into 1,00,00,000 Equity Shares of Rs 10/- each to Rs 15,00,00,000/- divided into 1,50,00,000 Equity Shares of Rs 10/- each and consequential amendments in the Memorandum and Articles of Association of the Company. 2. Authority to the Board to offer, issue and allot 6145000 Equity shares to the following allottees: i. NBZ Pharma Ltd (Promoter Group) - 6000000 No of Shares ii. Ms. Neha Rathi (Non Promoter) - 100000 No of Shares iii. Ms. Pravina Mehta (Non Promoter) - 25000 No of Shares iv. Mr. Sanjeev Nandu (Non Promoter) - 10000 No of Shares v. Mr. Mahendra A Chheda (HUF) (Non Promoter) - 10000 No of Shares of face value of Rs 10/- each at a subscription price of Rs 47.50/- per Equity share inclusive of premium of Rs 37.50/- per Equity Share, or at price as may be mutually agreed but not less than price calculated as per DIP Guidelines 13.1.1.1 being higher of the following: (a) The average of weekly high and low of the closing prices of the related shares quoted on the Stock exchange during the six months preceding the relevant date or (b) The average of weekly high and low of the closing prices of the related shares quoted on the stock exchange during the two weeks preceding the relevant data, per equity shares on a Preferential allotment basis for cash on the terms and conditions. (As Per BSE Announcement Website Dated on 29/05/2007) 

Peer Comparison

Company Market Cap
(Rs. in Cr.) 		P/E (TTM)
(x) 		P/BV (TTM)
(x) 		EV/EBIDTA
(x) 		ROE
(%) 		ROCE
(%) 		D/E
(x)
Ajanta Pharma 2,155.54 21.32 6.05 5.40 27.3 24.2 0.72
Plethico Pharma. 733.53 63.70 1.34 33.34 -5.5 3.8 1.08
Kappac Pharma 378.77 0.00 15.86 0.00 0.0 0.0 0.06
Sharon Bio-Med. 353.76 6.86 1.93 9.58 19.1 14.1 1.85
Bliss GVS Pharma 334.56 5.70 1.29 2.15 28.0 42.7 0.04
Syncom Formul. 325.69 93.62 3.90 13.86 4.3 6.7 0.09
Venus Remedies 296.65 5.19 0.77 3.54 17.7 16.9 0.72
Ahlcon Parent(I) 231.66 17.99 4.28 22.59 12.6 17.0 0.59
Amrutanjan Healt 187.17 15.45 2.13 9.89 12.6 16.3 0.23
Parenteral Drugs 186.91 0.00 0.96 58.93 -16.1 -0.7 0.86
Arvind Remedies 139.87 3.44 1.03 6.60 15.1 16.1 2.12
Combat Drugs 137.96 0.00 23.85 0.00 0.3 0.3 0.07
Zenotech Lab. 93.31 0.00 3.58 0.00 0.0 0.0 0.08
Hester Bios 89.87 9.27 1.32 4.56 14.4 20.6 0.35
Caplin Point Lab 89.22 5.74 2.95 1.38 29.3 33.1 0.30

Futures & Options Quote

 
Expiry Date
NA
Instrument: NA
Expiry Date: NA
Strike Price: NA
Open Price: NA
Average Price: NA
No. of Contracts Traded: NA
Open Interest: NA
Underlying: NA
Option Type: NA
Market Lot: NA
Previous Close: NA
Day’s High | Low: NA | NA
Turnover (Cr.): NA
Open Int. Change: NA | NA
View detailed F& O quotes >>

Key Information

Key Executives:

Mukund P Mehta , Managing Director 

Paresh P Mehta , Joint Managing Director 

Bhavin M Mehta , Director 

Mukesh Shah , Director 

Company Head Office / Quarters:
C-301/2 MIDC TTC Indl Area,
Pawane Village,
Thane,
Maharashtra-400705
Phone : 91-022-27670322/27680913/65144185
Fax : 91-022-27680912
E-mail : info@kilitch.com
Web : http://www.kilitch.in
Registrars:
Link Intime India Pvt Ltd
C-13 Pannalal Silk
Mills Cmpd LBS Marg
Bhandup West
Mumbai - 400 078

Fund Holding

 
Scheme Name No. of Shares
No data found

Calendar

Jun-2013
M T W T F S S
17 18 19 20 21 22 23
IPO
listNo IPO today
Economic Events
list Foreign Buying Japan Bonds (Yen)
list Foreign Buying Japan Stocks (Yen)
Results
list Coromandel Inter